Neurodegenerative Disease Program(s)

About Axonova

Axonova is a privately-held biotech firm with a hybrid strategy combining service-based revenue and proprietary drug development. Its core focus is neuroscience and regenerative medicine, utilizing cutting-edge platforms for drug discovery and preclinical validation. The company has completed a private funding round and reinvests approximately 20% of its revenue into R&D, aiming to license out validated preclinical candidates to larger pharmaceutical partners for further clinical development and commercialization.

Therapeutic Areas